Anesiva (ANSV) rallied in pre-market trading, after getting FDA approval for its sNDA to expand indication for Zingo to treat pain associated with blood draws in adults.
The stock was up 27 cents around 9:20 am ET, rising to 95 cents. If pre-market gains hold, the stock will open at its highest level since mid-December.
Friday, Anesiva said it received an approval from U.S. Food and Drug Administration or FDA for its supplemental New Drug Application or sNDA to expand the indication for Zingo to treat the pain associated with blood draws to include adults.
Zingo powder intradermal injection system was previously approved to treat the pain associated with peripheral IV insertions and blood draws in children three to 18 years of age. The notification was received according to PDUFA deadlines.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.